Expertise in
2
conditions

Monica Arnedos

Bordeaux, FR 
Expertise in
2
conditions
Bordeaux, FR 

Overview

Monica Arnedos practices practicing medicine in Bordeaux, France.

Ms. Arnedos is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Metastatic Brain Tumor, and Retinoblastoma.

She is actively involved in clinical research, co-authoring 84 peer reviewed articles and participating in 5 clinical trials.

Gender

Female

Locations

Bordeaux, France
Other Locations
Villejuif, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Identification of Early Markers of Response and Resistance to Trastuzumab in Patients With Localized Human Epidermal Growth Factor Receptor-2(HER-2)-Positive Breast Cancer Candidates for Breast Conserving Surgery
Identification of Early Markers of Response and Resistance to Trastuzumab in Patients With Localized Human Epidermal Growth Factor Receptor-2(HER-2)-Positive Breast Cancer Candidates for Breast Conserving Surgery
Enrollment Status: Completed
Publish Date: August 17, 2026
Intervention Type: Other
Study Phase: Not Applicable
Tracking Triple-negative Breast Cancer Evolution Through Therapy
Tracking Triple-negative Breast Cancer Evolution Through Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure
Study Phase: Not Applicable
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 15, 2025
Intervention Type: Drug
Study Drugs: AZD2014, AZD4547, AZD5363, AZD8931, Selumetinib, Vandetanib, Bicalutamide, Olaparib, Anthracyclines, Taxanes, Cyclophosphamide, DNA Intercalators, Methotrexate, Vinca Alkaloids, Platinum Based Chemotherapies, Bevacizumab, Mitomycin C, Eribulin, MEDI4736
Study Phase: Phase 2
A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer
A Phase II Randomized Trial Comparing Alpelisib and Fulvestrant Versus Chemotherapy as Maintenance Therapy in Patients With PIK3CA Mutated Advanced Breast Cancer
Enrollment Status: Terminated
Publish Date: November 28, 2022
Intervention Type: Drug
Study Drugs: Alpelisib, Chemotherapy
Study Phase: Phase 2
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women
Identification of the Molecular Alterations Associated With Resistance to Endocrine Therapy and Impacting Treatment With mTOR Inhibitor of HR+ Metastatic Breast Cancer in Post-menopausal Women
Enrollment Status: Completed
Publish Date: September 21, 2022
Intervention Type: Procedure
Study Phase: Not Applicable
View 4 Less Clinical Trials

84 Total Publications

Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: February 25, 2026

Frequently Asked Questions about Monica Arnedos

Is Monica Arnedos a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Monica Arnedos is classified as an Distinguished expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Monica Arnedos participate in research or clinical trials?

Yes. Monica Arnedos has published 84 articles and abstracts on conditions like Breast Cancer. You can view a list of Monica Arnedos's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Arnedos's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile